

Supplement Table S1. Comparative characteristics of DOACs pivotal trials and Palermo claims database.

	DABIGATRAN				RIVAROXABAN		APIXABAN		EDOXABAN			
Data source	RE-LY (2009)		Palermo claims database		ROCKET- AF (2011)	Palermo claims database	ARISTOTLE (2011)	Palermo claims database	ENGAGE AF-TIMI 48 (2013)		Palermo claims database	
Study design	Pivotal randomized trial		Observational, non-interventional, retrospective study		Pivotal, multicenter, randomized, double-blind, double-dummy, event-driven trial	Observational, non-interventional, retrospective study	Pivotal, randomized, double-blind trial	Observational, non-interventional, retrospective study	Pivotal, randomized, double-blind, double-dummy trial		Observational, non-interventional, retrospective study	
Study Years	Enrolment: December 2005- December 2007; Final follow-up visit: April 2009		January 2013- December 2017		Enrolment: December 2006- June 2009 Final follow-up visit: September 2010	January 2013- December 2017	Enrolment: December 2006- April 2010 Final follow-up visit: May 2011	January 2013- December 2017	Enrolment: November 2008- November 2010 Final follow-up visit: May 2013		January 2013- December 2017	
Study drugs	Dose-specific comparison				Non dose-specific comparison		Non dose-specific comparison		Dose-specific comparison			
Study Population	N=6,015	N=6,076	N= 794	N=635	N=7,131	N= 3,028	N=9,120	N= 2,113	N=7,034	N=7,035	N= 253	N= 269
	From: USA, Canada, Central Europe, Western Europe, Latin America, Asia and other		From: Palermo LHU		From: North America, Latin America, West Europe, East Europe, Asia Pacific	From: Palermo LHU	From: North America, South America, Europe or Asia Pacific	From: Palermo LHU	From: North America, Latin America, Western Europe, Eastern Europe, Asia pacific region and South Africa		From: Palermo LHU	